國立高雄大學圖資館 |

An introduction to bioanalysis of biopharmaceuticals

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	An introduction to bioanalysis of biopharmaceuticalsedited by Seema Kumar.
其他作者:	Kumar, Seema.
出版者:	Cham :Springer International Publishing :2022.
面頁冊數:	ix, 160 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	Biopharmaceutics.
電子資源:	https://doi.org/10.1007/978-3-030-97193-9
ISBN:	9783030971939$q(electronic bk.)

An introduction to bioanalysis of biopharmaceuticals
An introduction to bioanalysis of biopharmaceuticals[electronic resource] /edited by Seema Kumar. - Cham :Springer International Publishing :2022. - ix, 160 p. :ill., digital ;24 cm. - AAPS advances in the pharmaceutical sciences series,v. 572210-738X ;. - AAPS advances in the pharmaceutical sciences series ;3..

Bioanalytical Support in Drug Discovery and Development,- Monoclonal Antibodies -- Antibody Drug Conjugates (ADCS) -- Bispecifics and Fusion Proteins -- Emerging Modalities-Part A- (Gene Therapy and Cell Therapy) -- Emerging Modalities Part B (Peptides, Oligonucleotide Based Therapy, Vaccines.

The book provides a comprehensive review of the fundamental and practical aspects of bioanalytical support and the integral role it plays in the development of safe and efficacious biopharmaceutical drugs with speed and cost-effectiveness. The book focuses on a broad range of conventional and emerging biopharmaceutical modalities including monoclonal antibody-based therapeutics, gene therapy, cell therapy, peptides and oligonucleotides. The book starts with an introductory overview of bioanalysis showcasing the integral role it plays in understanding the drug disposition (pharmacokinetics/pharmacodynamics and immunogenicity) and the progression of bioanalytical strategy as the drug progresses through discovery and development stages of the program, taking into consideration the continually evolving regulatory landscape. The book further diversifies into individual biopharmaceutical modalities - monoclonal antibodies, antibody-drug conjugates, bispecifics, Fc-fusion proteins, gene therapies, cell therapies, peptides and oligonucleotides. The individual chapters focus on modality-specific bioanalytical assay strategies, critical reagents, assay formats, analytical platforms, associated bioanalytical challenges and mitigation strategies, industry best practices, and the latest understanding of regulatory guidance as applicable to the fast-growing biopharmaceutical landscape.

ISBN: 9783030971939$q(electronic bk.)

Standard No.: 10.1007/978-3-030-97193-9doiSubjects--Topical Terms:

224951
Biopharmaceutics.

LC Class. No.: RM301.4 / .I57 2022

Dewey Class. No.: 615.7

An introduction to bioanalysis of biopharmaceuticals
LDR:02730nmm a2200325 a 4500 001 628779
003 DE-He213
005 20220823133540.0
007 cr nn 008maaau
008 230224s2022 sz s 0 eng d
020 $a 9783030971939$q(electronic bk.)
020 $a 9783030971922$q(paper)
024 7 $a 10.1007/978-3-030-97193-9 $2 doi
035 $a 978-3-030-97193-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.4 $b .I57 2022
072 7 $a PSA $2 bicssc
072 7 $a SCI086000 $2 bisacsh
072 7 $a PSA $2 thema
082 0 4 $a 615.7 $2 23
090 $a RM301.4 $b .I61 2022
245 0 3 $a An introduction to bioanalysis of biopharmaceuticals $h [electronic resource] / $c edited by Seema Kumar.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a ix, 160 p. : $b ill., digital ; $c 24 cm.
490 1 $a AAPS advances in the pharmaceutical sciences series, $x 2210-738X ; $v v. 57
505 0 $a Bioanalytical Support in Drug Discovery and Development,- Monoclonal Antibodies -- Antibody Drug Conjugates (ADCS) -- Bispecifics and Fusion Proteins -- Emerging Modalities-Part A- (Gene Therapy and Cell Therapy) -- Emerging Modalities Part B (Peptides, Oligonucleotide Based Therapy, Vaccines.
520 $a The book provides a comprehensive review of the fundamental and practical aspects of bioanalytical support and the integral role it plays in the development of safe and efficacious biopharmaceutical drugs with speed and cost-effectiveness. The book focuses on a broad range of conventional and emerging biopharmaceutical modalities including monoclonal antibody-based therapeutics, gene therapy, cell therapy, peptides and oligonucleotides. The book starts with an introductory overview of bioanalysis showcasing the integral role it plays in understanding the drug disposition (pharmacokinetics/pharmacodynamics and immunogenicity) and the progression of bioanalytical strategy as the drug progresses through discovery and development stages of the program, taking into consideration the continually evolving regulatory landscape. The book further diversifies into individual biopharmaceutical modalities - monoclonal antibodies, antibody-drug conjugates, bispecifics, Fc-fusion proteins, gene therapies, cell therapies, peptides and oligonucleotides. The individual chapters focus on modality-specific bioanalytical assay strategies, critical reagents, assay formats, analytical platforms, associated bioanalytical challenges and mitigation strategies, industry best practices, and the latest understanding of regulatory guidance as applicable to the fast-growing biopharmaceutical landscape.
650 0 $a Biopharmaceutics. $3 224951
650 0 $a Pharmaceutical biotechnology. $3 189023
650 1 4 $a Biological Sciences. $3 503847
650 2 4 $a Pharmaceutics. $3 913065
650 2 4 $a Biological Chemistry. $3 923910
650 2 4 $a Pharmacology. $3 218135
650 2 4 $a Cell Biology. $3 274165
700 1 $a Kumar, Seema. $3 933209
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a AAPS advances in the pharmaceutical sciences series ; $v 3. $3 559046
856 4 0 $u https://doi.org/10.1007/978-3-030-97193-9
950 $a Biomedical and Life Sciences (SpringerNature-11642)